摘要
目的:探讨尿激酶联合阿司匹林治疗慢性肺心病心力衰竭的临床疗效及安全性。方法:将80例慢性肺心病心力衰竭患者随机分为尿激酶联合阿司匹林组(观察组,40例)和阿司匹林组(对照组,40例),两组均常规使用倍他乐克、利尿剂、洋地黄类药,观察2周。结果:观察组有效率为85%,对照组有效率为65%,两组有效率比较,差异有统计学意义。结论:尿激酶联合阿司匹林治疗慢性肺心病心力衰竭是安全有效的。
Objective:To investigate the clinical efficacy and safety of Urokinase and Aspirin in the treatment of chronic pulmonary heart disease with heart failure.Methods:80 patients of chronic pulmonary heart disease with heart failure were randomly divided into Urokinase and Aspirin group (observation group,40 cases) and Aspirin group (control group,40 cases),and received conventional therapy of Metoprolol,Diuretics,Digitalis medicines,observed 2 weeks.Results:The effective rate of observation group was 85%,the control group was 65%,the efficiency of two groups had significant differ ences.Conclusion:Urokinase and Aspirin in the treatment of chronic pulmonary heart disease with heart failure is safe and effective.
出处
《中国医药导报》
CAS
2010年第23期79-80,共2页
China Medical Herald
关键词
慢性肺心病
心力衰竭
尿激酶
阿司匹林
Chronic pulmonary heart disease
Heart failure
Urokinase
Aspirin
